Source comparison
AOD-9604 CJC-1295 Stack Fat Loss Muscle Gain Protocol 2026 Comparison
Primary Mechanism Beta-3 adrenergic lipolysis GHRH receptor amplification → pulsatile GH release Dual pathway: lipolysis + GH-mediated anabolism Stack addresses both fat oxidation and lean mass retention. Solo protocols target only one mechanism Fat Loss Patte
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Beta-3 adrenergic lipolysis
- GHRH receptor amplification → pulsatile GH release
- Dual pathway: lipolysis + GH-mediated anabolism
- Stack addresses both fat oxidation and lean mass retention. Solo protocols target only one mechanism
- Fat Loss Pattern
- Preferential visceral fat reduction (10-15% over 12 weeks)
- Modest whole-body lipolysis (5-8% over 12 weeks)
- Accelerated visceral reduction (12-18%) + preserved muscle mass
- Stack produces fastest visceral fat loss without muscle catabolism
- Lean Mass Preservation
- Neutral. No anabolic signaling
- Strong. GH pulse amplitude supports nitrogen retention
- Strong. CJC-1295 provides anabolic environment while AOD-9604 targets fat
- Critical for recomposition. AOD-9604 alone risks muscle loss in deficit
- Injection Frequency
- Daily (250-500 mcg)
- Twice weekly (500 mcg-1 mg per dose)
- Daily AOD-9604 + biweekly CJC-1295
- Stack requires more frequent administration than CJC-1295 alone
- Appetite Effect
- None. Does not cross blood-brain barrier
- Moderate increase (GH-driven ghrelin elevation)
- Moderate increase from CJC-1295 component only
- AOD-9604 doesn't suppress appetite; caloric deficit still required
- Research Cost (12-week protocol)
- $180-$240 (AOD-9604 only)
- $200-$280 (CJC-1295 only)
- $380-$520 (both peptides)
- Stack costs 90-100% more than single-peptide protocols